In randomized managed trials, There are 2 treatment alternatives currently thought of the conventional of treatment in Guillain-Barré syndrome (GBS). These contain either intravenous immunoglobulin (IVIG) or plasma exchange. IVIG is thought to act by its immune-modulating motion; on the other hand,